Recombinant SARS-CoV-2, S1-mFc Protein
| Code | Size | Price |
|---|
| LEI-S855-100ug | 100 ug | £532.00 |
Quantity:
| LEI-S855-500ug | 500 ug | £1,657.00 |
Quantity:
| LEI-S855-1.0mg | 1.0 mg | £2,179.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Virus
Regulatory Status: RUO
Shipping:
Ice Packs
Storage:
This recombinant protein may be stored as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This recombinant protein is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of proteins, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This recombinant protein is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of proteins, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Long Description:
This recombinant SARS-CoV-2 S1 protein is with the mFc tag. The SARS-CoV-2 Spike (S) Protein consists of the S1 and S2 domains. The S1 subunit contains the N-terminal domain (NTD) and receptor-binding domain (RBD). The S1 subunit recognizes and binds to angiotensin-converting enzyme 2 (ACE2) receptors on target cells through the RBD portion, and subsequent conformational changes in S2 allow for fusion between the viral envelope and host cell membrane. SARS-CoV-2 is closely related to the SARS virus, which was first identified in 2002-20031. Both SARS-CoV and SARS-CoV-2 utilize the ACE2 cell receptor to gain entry into cells, with SARS-CoV-2 binding with higher affinity2. Vaccine and therapeutic development are targeting portions of the spike protein, including the S1 portion3.
NCBI Gene:
43740568
Purity:
>95% by SDS Page
Target:
SARS-CoV-2
References
1. Quinlan et al. bioRxiv: 2020.
2. Wrapp et al. Science: 2020.
3. Tai et al. Nature: 2020.